Simvastatin, sildenafil and their combination in monocrotaline induced pulmonary arterial hypertension.
OBJECTIVE
Pulmonary arterial hypertension (PAH) is a life threatening disease characterized by progressive pulmonary arterial occlusion which may ultimately result in death. Currently, the available treatments are diverse, but no therapy alone can reverse the disease process although they may have some clinical benefits. This study was designed to investigate single and combination therapy of simvastatin and sildenafil, which have different mechanisms of action, in monocrotaline (MCT)-induced PAH.


METHODS
[corrected] Rats were randomized to receive saline (control, n=8) or MCT treatment (n=32). MCT treated rats were randomized to vehicle, simvastatin (2 mg/kg/day), sildenafil (25 mg/kg/day) and a combination simvastatin and sildenafil (n=8, respectively). Three weeks later, hemodynamic study and histologic changes of pulmonary arterioles were measured. Proliferating cell nuclear antigen (PCNA) as well as Western blot for endothelial nitric oxide synthase (eNOS) were performed.


RESULTS
Systolic right ventricular pressure was significantly decreased in monotherapy groups (simvastatin and sildenafil) and the combination group compared to MCT group (p<0.05). Right ventricular hypertrophy and medial wall thickness of pulmonary arterioles were significantly attenuated with sole and combination therapy (p<0.05). However, combination therapy did not confer additive benefits over monotherapy. Altered PCNA or eNOS in lung tissue was normalized by either monotherapy or combination therapy.


CONCLUSIONS
The results suggest that either simvastatin or sildenafil has the therapeutic potential in MCT-induced PAH, although combination therapy of these two drugs has failed to show greater benefits in the study.
Department of Pediatrics, Dongguk University School of Medicine, Gyeongju, Korea.
Dong Seok
DS
Lee
Yung Kyu
YK
Kim
Yong Wook
YW
Jung
Am J Respir Crit Care Med. 2004 Jan 1;169(1):39-45
12958054
Biochem Biophys Res Commun. 2006 Jan 6;339(1):59-64
16297860
J Intern Med. 2005 Sep;258(3):199-215
16115293
Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H938-45
12750068
Circulation. 2003 Jul 1;107(25):3230-5
12796132
Eur Respir J. 2005 Nov;26(5):858-63
16264047
Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1712-9
11701455
Respirology. 2006 Jan;11(1):6-17
16423196
N Engl J Med. 2005 Nov 17;353(20):2148-57
16291984
Pharmacol Ther. 1999 Dec;84(3):413-28
10665838
J Biol Chem. 1997 Dec 12;272(50):31725-9
9395516
Indian Heart J. 2002 Jul-Aug;54(4):404-9
12462669
Interact Cardiovasc Thorac Surg. 2007 Oct;6(5):608-13
17670742
N Engl J Med. 2004 Sep 30;351(14):1425-36
15459304
J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):13S-24S
15194174
Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L668-76
16698853
Am J Physiol Lung Cell Mol Physiol. 2007 May;292(5):L1105-10
17277047
Am J Respir Crit Care Med. 2005 Jun 1;171(11):1292-7
15750042
Pulm Pharmacol Ther. 2010 Oct;23(5):456-64
20188205
Chest. 2007 Jun;131(6):1917-28
17565025
Circulation. 2003 Sep 30;108(13):1640-5
12963647
J Am Coll Cardiol. 2004 Apr 7;43(7):1149-53
15063421
Eur Respir J. 2009 Oct;34(4):948-57
19797670
Am J Physiol Lung Cell Mol Physiol. 2007 Oct;293(4):L933-40
17675370
J Pharm Pharm Sci. 2009 Feb 04;11(2):118s-130s
19203474
Chest. 2005 Apr;127(4):1446-52
15821229